NovImmune

novimmune.com

NovImmune SA

14 ch. des Aulx
1228 Plan-les-Ouates
Switzerland

Phone

novimmune.com
Contact
Profile News

About NovImmune

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.

Read more about NovImmune

Advertisement

Revolutionize your production: real-time Raman analysis for maximum efficiency
Revolutionize your production: real-time Raman analysis for maximum efficiency
Efficient inline analysis for liquids and solids
Efficient inline analysis for liquids and solids
User-friendly software for effortless Design of Experiments (DoE)
User-friendly software for effortless Design of Experiments (DoE)

News about NovImmune

NovImmune

19-Dec-2011 | research and development

Genentech Initiates First-in-Human Study with NovImmune’s Anti-IL17 Antibody

NovImmune announced that Genentech, a member of the Roche Group, initiated a First-in-Human study with anti-IL-17 (NI-1401, RG7624), a fully human ...

Read news
NovImmune

26-Sep-2011 | research and development

NovImmune Initiates a Proof-of-Concept Study in Primary Biliary Cirrhosis (PBC)

NovImmune announced that a Proof-of–Concept (PoC) study with NI-0801, a fully human monoclonal antibody neutralizing the CXCL10/Interferon-gamma-inducible ...

Read news
NovImmune

27-May-2011 | people

NovImmune Nominates Klaus Strein as New Member of the Board of Directors

NovImmune announced that Klaus Strein was nominated member of the Board of Directors.Prof Klaus Strein holds a Ph.D. in chemistry from the University of ...

Read news
NovImmune

27-Jul-2010 | business & finance

NovImmune enters exclusive antibody licensing agreement with Genentech

NovImmune announced that it successfully entered into an exclusive licensing agreement with Genentech Inc. a member of the Roche Group for a proprietary ...

Read news
NovImmune

14-Jul-2009 | research and development

NovImmune successfully completes NI-0801 Phase I clinical study

NovImmune announced the successful completion of the first phase I clinical study with its fully human monoclonal antibody NI-0801 targeting the chemokine ...

Read news
NovImmune

21-Apr-2009 | science

Panspecific antibodies: Novimmune successful in multiple specificities

NovImmune announced the description of a single antibody engineered for double antigen binding specificity involving chemokines as targets. The work was ...

Read news
Show more news about NovImmune

Here you will find NovImmune SA